Bora Appoints Industry Veteran as Chief Commercial Officer TAIPEI, TAIWAN, May 13, 2025 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, today announced the appointment of Jean-Baptiste (“JB”) Agnus as Chief Commercial Officer. In this role, he will lead Bora’s commercial strategy for its sterile injectables and...
Bora Wins Prestigious CDMO Leadership Awards TAIPEI, TAIWAN, March 20, 2025 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, today celebrated winning three Outsourced Pharma Leadership Awards: Best New or Transformed CDMO, Biologics - Global, and Small Molecule Dosage Form - Global. The awards were presented at a...
Bora Biologics Announces Strategic Collaboration to Accelerate Key CMC Development of DotBio’s Tri-Specific Antibody to Treat Cancer TAIPEI, TAIWAN – January 9th, 2025 – Bora Biologics, a fast-growing division of leading contract development and manufacturing organization (CDMO), Bora Pharmaceuticals, today announced that it will support DotBio, a Singaporean biopharmaceutical company...
Bora Pharmaceuticals Announces Unveiling of New Multi-Purpose Small Molecule Site in Zhongli, Taiwan Taipei, Taiwan (January 6, 2025) – Bora Pharmaceuticals Co., Ltd. (“Bora,” TWSE: 6472), a global cGMP contract development and manufacturing organization (CDMO), is pleased to announce the grand unveiling of its new small molecule dose form facility in Zhongli, Taiwan. This represents another...